As Technologies for Nucleotide Therapeutics Mature, Products Emerge

As Technologies for Nucleotide Therapeutics Mature, Products Emerge

The long path from initial research on oligonucleotide therapies to approval of antisense products is not unfamiliar. This lag resembles those encountered with monoclonal antibodies, gene therapies, and many biological targets and is consistent with studies of innovation showing that technology matu...

Full description

Bibliographic Details
Main Authors: Jennifer M. Beierlein, Laura M. McNamee, Fred D. Ledley
Format: Article
Language:English
Published: Elsevier 2017-12-01
Series:Molecular Therapy: Nucleic Acids
Subjects:
oligonucleotide therapeutics
antisense
ribozyme
small interfering RNA
RNAi
miRNA
FDA approval
technology forecasting
data analytics
technology management
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253117302810

Internet

http://www.sciencedirect.com/science/article/pii/S2162253117302810

Similar Items